Molecular Therapy Review Time

The official ScienceDirect insights page is useful, but it tells only part of the story.

It tells you:

• the journal positions itself as a leading venue for gene transfer, vector design, stem cell manipulation, and therapeutic platforms
• the current official public timeline is 136 days from submission to acceptance
• the journal supports both subscription and open-access routes
• the journal is indexed broadly and carries strong Scopus and JCR metrics

It does not tell you:

• a public median desk-rejection time
• a public median first-decision time
• how much faster transferred or unusually strong cases might move

That is why the safest planning model is still "multi-month flagship review cycle."

That is the practical author model. Even if one reviewed case moves fast, the journal itself is telling you not to build a schedule around that.

The journal sometimes feels fast because authors see a smooth accepted case, or because a well-positioned therapy paper can move cleanly through section editors and reviewers.

That can happen when:

• the therapeutic platform consequence is obvious early
• the delivery or engineering logic is already mature
• the translational claim is proportionate to the data
• the manuscript clearly belongs in flagship Molecular Therapy rather than a narrower family journal

But the public official number still tells you that this is not the norm.

The slower cases are usually not administrative accidents. They are papers that force the journal to decide how much field-level therapeutic consequence is really there.

Common sources of delay are:

• disease-specific efficacy stories with weaker platform consequence
• missing durability, safety, or manufacturability context
• revisions that must sharpen the therapy logic rather than just the writing
• papers that might actually belong in a narrower Molecular Therapy family lane

That is why the elapsed time often reflects journal identity more than reviewer mood.

That profile matches the timing posture. A journal like this is deciding field ownership, not just technical correctness.

This matters because timing disappointment is often a journal-ownership mistake.

Directionally, the open citation signal is effectively flat, down from 9.43 in 2023 to 9.40 in 2024. That stability matters because it suggests the journal is not in a rapid transition phase. The editorial identity is mature and stable, which usually means authors should expect consistent, not experimental, handling standards.

Review-time data hides the key distinction at Molecular Therapy:

• one smooth accepted case does not define the journal
• official timeline data matter more than anecdotal fast cases
• the real timing variable is whether the manuscript changes the therapeutic field, not just whether it works in one indication

That is why the safer planning model is the official one.

In our pre-submission review work with Molecular Therapy manuscripts, the timing mistake we see most often is authors treating the journal like a reward for any good gene-therapy or cell-therapy paper.

It is not.

The papers that move best here usually have:

• a therapeutic advance that matters beyond one disease
• a platform or delivery logic that is load-bearing
• translational claims that are proportionate to the evidence
• fewer signs that the paper is actually a narrower family-journal fit

Those traits improve timing because they reduce the chance of a long editorial debate about what kind of paper this really is.

For Molecular Therapy, speed matters less than therapeutic field consequence and platform fit.

That is why the better next reads are:

• Molecular Therapy submission guide
• Molecular Therapy impact factor
• How to avoid desk rejection at Molecular Therapy
• How to choose the right journal for your paper

A Molecular Therapy fit check is usually more useful than relying on the fastest anecdote you can find.

Molecular Therapy review time should be planned as a several-month flagship-journal process. The safest public anchor is the official 136-day submission-to-acceptance number. Authors should not build their expectations around the much faster but tiny community sample.